The historic rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its future within the broader market now triggers questions about future gains. Copycat versions are diminishing exclusivity , leading to worries that supporting companies heavily reliant to Viagra's once-dominant standing could be a dangerous decision